US Oncology Research Affiliated Investigators participate in studies presented at the American Society of Hematology Annual Meeting

McKesson's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

December 06, 2013

Leading investigators affiliated with US Oncology Research involved in six oral clinical study presentations, 19 posters and two publications

The Woodlands, Texas (Dec. 6, 2013) - More than 25 leading investigators affiliated with US Oncology Research participated in 27 studies that will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, La. at the Ernest N. Morial Convention Center.  ASH will take place Dec. 7-10 and is an educational and scientific program that helps hematology professionals stay up-to-date on the latest research, therapies, and tools needed to be successful in their field.

Roger Lyons, M.D., F.A.C.P., medical oncologist/ hematologist and president of Cancer Care Centers of South Texas (CCCST), an affiliate of US Oncology Research, is co-author of two studies being featured as oral presentations. One study titled Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients will be presented on Dec. 9 at 7:00am and will take an in-depth look into whether recently approved anti-coagulants are effective in cancer patients who experience blood clots.

Dr. Lyons is also co-author of the study titled Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-1,  which will be featured as an oral presentation on Dec. 9 at 11:45am. This is a follow up to a previous study that led to the approval of Ruxolitinib, a JAK-2 inhibitor, as the only treatment for Myelofibrosis. Dr. Lyons says this trial studied patients during a longer period of time to take a more in-depth look at the drug's efficacy, toxicity and survival outcomes.

"I believe we are entering into an exciting era where, during the next five to eight years, we will see enormous numbers of small, targeted studies focused on improving treatments for hematologic diseases and blood disorders," said Dr. Lyons. "These could be dramatic and game changing, which is always exciting for physicians and, most importantly, for patients. Hematology continues to be at the forefront of innovation, advanced treatment options and new approaches. This is evident by the number of high-quality findings being presented at meetings such as ASH."

In addition to the two studies above, 25 other US Oncology Research affiliated studies will be featured as oral presentations, posters or publications at this year's meeting. A full list of US Oncology Research affiliated studies on display at the ASH Annual Meeting is below. For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-825-9927.

Oral Presentations:

1. Monday, Dec. 9: 7:00am, Room 278-282, #211

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Gary E. Raskob, Harry Buller, Pantep Angchaisuksiri, Doyeun Oh, Zoltan Boda, Roger M. Lyons, Jeffrey I. Weitz, George Zhang, Hans J. Lanz, Michele Mercuri

2. Monday, Dec. 9: 11:30am, La Nouvelle Ballroom AB, #371

A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial

Michael Crump, Sirpa Leppä, Luis E. Fayad, Je-Jung Lee, Alice Di Rocco, Michinori Ogura, Hans Hagberg, Frederick Schnell, Robert M. Rifkin, Andreas Mackensen, Fritz Offner, Lauren Pinter-Brown, Sonali M. Smith, Kensei Tobinai, Su-Peng Yeh, Jun Zhu, Marjo Hahka-Kemppinen, Donald Thornton, Peipei Shi, Boris Lin, Brad S. Kahl, Norbert Schmitz, Kerry J. Savage, Thomas M. Habermann

3. Monday, Dec. 9: 11:45am, New Orleans Theatre C, #396

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. Dipersio, John V. Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr., Murat O. Arcasoy, Elizabeth Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor A. Sandor, Hagop M. Kantarjian

4. Monday, Dec. 9: 4:00pm, Room 220-222, #528

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, Tadeusz Robak, Ann Janssens, K. Govindbabu, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas Boyd, Marco Montillo, Astrid McKeown, Jodi L. Carey, Ira V. Gupta, Chai-Ni Chang, Steen Lisby, Fritz Offner

5. Tuesday, Dec. 10: 7:30am-9:00am, Hall F, #LBA-6

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Richard R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin, Nicole Lamanna, Michael Hallek, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Susan M. O'Brien

6. Tuesday, Dec. 10: 7:45am, La Nouvelle Ballroom AB, #848

A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL And Other B-Cell Lymphomas

Nancy L. Bartlett, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Celeste M. Bello, Jane N. Winter, Yin Yang, Dana A. Kennedy, Eric D. Jacobsen


7. Saturday, Dec. 7: 5:30pm-7:30pm, Hall E, #1634

Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Jeff P. Sharman,Leonard Klein, Michael Boxer, Kathryn S. Kolibaba, Michael J. Hawkins, Julie A. Di Paolo, Jing Hu, Anita Reddy, Feng Jin, Flordeliza Melchor-Khan, Christopher A. Yasenchak

8. Saturday, Dec. 7: 5:30pm-7:30pm, Hall E, #1630

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, Thomas J. Kipps

9. Saturday, Dec. 7: 5:30pm-7:30pm, Hall G, #1941

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Robert M. Rifkin,Clara Chen, Rahul Dhanda, Debra Rembert, Abbie Ba-Mancini, Esprit Ma, Yanyan Zhu, Edward Dow, Liviu Niculescu

10. Saturday, Dec. 7: 5:30pm-7:30pm, Hall G, #1966

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Ruben Niesvizky, Ian Flinn, Robert M. Rifkin, James Essell, Yousuf Gaffar, Thomas Warr,  Rachel Neuwirth, Abbie Ba-Mancini, Yanyan Zhu, Liviu Niculescu, James Reeves

11. Saturday, Dec. 7: 5:30pm-7:30pm, Hall G, #1934

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma

James R. Berenson, Leonard Klein, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Alan Cartmell

12. Saturday, Dec. 7: 5:30pm-7:30pm, Hall E, #1632

Clinical Activity Of Idelalisib (GS-1101), A Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Steven E. Coutre, John P. Leonard, Jacqueline C. Barrientos, Sven De Vos, Ian Flinn, Richard R. Furman, Jennifer R. Brown, Nina Wagner-Johnston, Don M. Benson, Jr., Marshall T. Schreeder, Jeff P. Sharman, Thomas Boyd,  Stephen Spurgeon, Andrew D. Zelenetz, Nicole Lamanna, Thomas J. Kipps, Brad S. Kahl, Celeste M. Bello, Jan A. Burger, Kanti R. Rai, Roger D. Dansey, Yeonhee Kim, Leanne M. Holes, Mirella Lazarov, Ronald L. Dubowy, Susan M. O'Brien

13. Sunday, Dec. 8: 6:30pm-8:30pm, Hall G, #3207

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Rafat Abonour, Jatin J. Shah, Brian Durie, Howard Terebelo, Cristina J. Gasparetto, Jayesh Mehta, Mohit Narang, Sachdev P. Thomas, Kathleen Toomey, Kristen A Sullivan, Shankar Srinivasan, Yasir Nagarwala, Robert M. Rifkin

14. Sunday, Dec. 8: 6:30pm-8:30pm, Hall E, #2733

Association Between Treatment Adherence and Response Among Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The Community Setting

Nicholas J. Di Bella,Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Rahul Dhanda, Zachary Cain, Tony Okoro, Bjorn Bolinder, Debra Patt, Elias J. Jabbour

15. Sunday, Dec. 8: 6:30pm-8:30pm, Hall E, #2775

48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

Roger M. Lyons, Billie J. Marek, Carole S. Paley, Jason Esposito, Katie McNamara, Lawrence Garbo, Nicholas DiBella, Guillermo Garcia-Manero

16. Sunday, Dec. 8: 6:30pm-8:30pm, Hall E, #2978

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Paul J. Shaughnessy, Ann Kelley, Roberta Tremper, Jonathan Tinker, Carlos Bachier, Joseph Holahan, Roger M. Lyons, Charles F. LeMaistre

17. Sunday, Dec. 8: 6:30pm-8:30pm, Hall E, #2878

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With  Bendamustine, Fludarabine or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Sven De Vos, Richard R. Furman, Jacqueline C. Barrientos, Nina D. Wagner-Johnston, Ian Flinn, Jeff P. Sharman, Thomas Boyd, John P. Leonard, Roger D. Dansey, Yeonhee Kim, Leanne M. Holes, Ronald L. Dubowy, Steven E. Coutre

18. Sunday, Dec. 8: 6:30pm-8:30pm, Hall G, #3178

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Shaji K. Kumar, Ann E. Engebretson, Francis K. Buadi, Martha Q. Lacy, Angela Dispenzieri, Mei Sheng Duh, Marie-Hélène Lafeuille, Patrick Lefebvre, Wendy Y. Cheng, Katherine Dea, Mark Yap, Shanmugapriya Saravanan, Iwen Pan, Debra Rembert, Rahul Dhanda, Debra Patt, Liviu Niculescu, Abbie Ba-Mancini, Esprit Ma, Maureen Quick, S. Vincent Rajkumar

19. Monday, Dec. 9: 6:00pm-8:00pm, Hall E, #4176

Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability

Jacqueline C. Barrientos, Nina D. Wagner-Johnston, Sven De Vos, Steven E. Coutre, Marshall T. Schreeder, Ian Flinn, Jeff P. Sharman, Kanti R. Rai, John P. Leonard, Roger Dansey, Yeonhee Kim, Leanne M. Holes, Henry Adewoye, Richard R. Furman

20. Monday, Dec. 9: 6:00pm-8:00pm, Hall E, #4180

A Phase 1 Study Of The Selective PI3Kd Inhibitor Idelalisib (GS1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, Sven De Vos, John P. Leonard, Jacqueline C. Barrientos, Marshall T. Schreeder, Ian W. Flinn, Jeff P. Sharman, Thomas Boyd, Nathan Fowler, Kanti R. Rai, Yeonhee Kim, Leanne M. Holes, Roger Dansey, Thomas M. Jahn, Steven E. Coutre

21. Monday, Dec. 9: 6:00pm-8:00pm, Hall G, #4389

A Phase 2 Study Of Single-Agent Brentuximab Vedotin for Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results

Christopher A. Yasenchak, Robert Chen, Jeff P. Sharman, Ralph V. Boccia, Beata Holkova, Peter J. Rosen, Jonathan W. Friedberg, Megan M. O'Meara, Andres Forero-Torres

22. Monday, Dec. 9: 6:00pm-8:00pm, Hall E, #4163

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study

Susan O'Brien, Richard R. Furman, Nathan Fowler, Steven E. Coutre, Jeff P. Sharman, Kristie A. Blum, Jan A. Burger, Jeffrey A. Jones, William G. Wierda, Emiliano Mugnaini, Ian Flinn, Ranjana H. Advani, Kathryn S. Kolibaba, Yun Shaw, Fong Clow, Danelle F. James, Alvina D. Chu, John C. Byrd

23. Monday, Dec. 9: 6:00pm-8:00pm, Hall G, #4342

Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies

Carlo Gambacorti-Passerini, Keizo Horibe, Fadi Braiteh, Hui-qiang Huang, Yuankai Shi, Matthew H. Taylor, Nicoletta Brega, Jolanda Paolini, Paulina Selaru, Tae Min Kim

24. Monday, Dec. 9: 6:00pm-8:00pm, Hall E, #4090

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Veena Fauble, Robyn M. Emanuel, Holly Lynn Geyer, Amylou Constance Dueck, Nicolaus Kroeger, Bart L. Scott, Aaron T. Gerds, Uday R. Popat, Sergio A. Giralt, Vikas Gupta, David Ross, Emily Knight, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, Elisabeth Ejerblad, Gunnar Birgegard, Peter Johansson, Bjorn Andreasson, Federico Sackmann, Jean-Loup Demory, Constantine S. Tam, Jan J. Michiels, Deepti H. Radia, Michael Boxer, Ruben A. Mesa

25. Monday, Dec. 9: 6:00pm-8:00pm, Hall G, #4587

Differential Gene Expression Analysis Predicts For Response To Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host Disease (cGVHD)

Alan M. Miller,Reva Schneider, Estil A. Vance, Edward Agura, Sheila Powell, Virginia Pascual, Indira Munagala, Huanying Qin


26. Randomized, Placebo-Controlled, Phase I/II Trial Of the Thrombopoietin Receptor Agonist Eltrombopag in Thrombocytopenic Patients with Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia - A Subgroup Analysis of Patients Receiving Concomitant Anticancer Therapy 

Uwe Platzbecker, Raymond S.M. Wong, Amit Verma, Camille Abboud, Sergio Araujo, Tzeon-Jye Chiou, John Feigert, Su-Peng Yeh, Katharina Götze, Norbert-Claude Gorin, Peter Greenberg, Suman Kambhampati, Yoo-Jin Kim, Je-Hwan Lee, Roger Lyons, Marco Ruggeri, Valeria Santini, Gregory Cheng, Jun Ho Jang, Chien-Yuan Chen, Souria Dougherty, Frank Mannino, Yasser Mostafa Kamel, Geoffrey Chan, Nicole Stone, Aristoteles Giagounidis

27. Obinutuzumab (GA101) 1000 mg vs 2000 mg In Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase II GAGE Trial (GAO4768g) 

Joseph Flynn, John Byrd, Thomas Kipps, Michael Boxer, Kathryn Kolibaba, N. Tyson, Jamie Hirata, Jeff P. Sharman

Numerous clinical studies led by US Oncology Research affiliated physicians have been prominently featured at conferences held around the world, including the American Society of Clinical Oncology (ASCO) Annual Meeting, the San Antonio Breast Cancer Symposium (SABCS), and the European Society for Medical Oncology (ESMO) European Cancer Congress. From January to October 2013, more than 100 independent registration and investigator-initiated studies were published in peer reviewed journals by investigators associated with US Oncology Research and/or The US Oncology Network. These studies featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 80 research sites and 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 56,000 patients in nearly 1,300 trials since inception in 1992 and have played a role in 47 FDA-approved cancer therapies. For more information call (800) 482-6700 or visit

News Source : US Oncology Research Affiliated Investigators participate in studies presented at the American Society of Hematology Annual Meeting

Copy this html code to your website/blog to embed this press release.